Vernell Flood, APRN
Psychiatric/Mental Health, Adult · Norcross, GANPI 1871584888
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 24.9% of the total. Among psychiatric/mental health, adult clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $36.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$689
- Neurocrine Biosciences, Inc.$554
- AbbVie$448
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$370
- Teva Pharmaceuticals USA, Inc.$265
- Otsuka America Pharmaceutical, Inc.$245
- plus $196 from 5 others
What the payments were for
- Food & beverage$2,72198%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $689 |
| Neurocrine Biosciences, Inc. | 9 | $554 |
| AbbVie | 19 | $448 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $370 |
| Teva Pharmaceuticals USA, Inc. | 9 | $265 |
| Otsuka America Pharmaceutical, Inc. | 8 | $245 |
| Alkermes, Inc. | 6 | $116 |
| Indivior Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$384
- INGREZZA$372
- CAPLYTA$237
- UZEDY$120
- VRAYLAR$119
- ABILIFY ASIMTUFII$115
- ABILIFY MAINTENA$115
How this compares
$2,768 in reported general payments places this provider in the 95th percentile of 22 psychiatric/mental health, adult providers in Georgia.
See all psychiatric/mental health, adult providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 107 | $349,077 |
| Invega TrinzaPaliperidone Palmitate | 12 | $106,474 |
| Abilify MaintenaAripiprazole | 16 | $47,345 |
| VraylarCariprazine Hcl | 20 | $29,054 |
| Fluphenazine Hcl | 17 | $5,838 |
| Lurasidone Hcl | 14 | $5,624 |
| Ziprasidone Hcl | 41 | $3,103 |
| Aripiprazole | 20 | $3,063 |
| Haloperidol Decanoate | 53 | $2,168 |
| Fluvoxamine Maleate | 21 | $1,757 |
| Olanzapine | 98 | $1,740 |
| Benztropine Mesylate | 112 | $1,663 |
| Bupropion XlBupropion Hcl | 56 | $1,466 |
| Risperidone | 104 | $1,283 |
| Buspirone Hcl | 78 | $1,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $689 | $455,550119 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $245 | $47,34516 claims |
| AbbVieVraylar | $448 | $29,05420 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $265 | $72813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 psychiatric/mental health, adult providers in Georgia.
Other psychiatric/mental health, adult in Norcross
- Julie BurkeCarrollton$78K
- Dene BellamyDecatur$1K
- Jennifer SimondsAugusta$1K
- Wendy Barnes-MellstromSmyrna$800
- Joann KaragaAtlanta$691
- Barbara HartsfieldAtlanta$588
- Jackie WilliamsAtlanta$346
- Pamela RatajczakMilledgeville$247
- Ailaf DarfoorLawrenceville$213
- Carmen TurnerMoultrie$206
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.